PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete If Known		
				Application Number	10/644,576	
11	<b>NFORMATION</b>	1 DI	SCLOSURE	Filing Date	August 20, 2003	
S	TATEMENT I	3Y /	APPLICANT	First Named Inventor	Connie Sanchez	
				Art Unit	N/A	
l	(Use as many sh	eets as	s necessary)	Examiner Name	Not Yet Assigned	
Sheet	1	of	2	Attorney Docket Number	05432/100M919-US5	

	U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where			
	No.1	Number-Kind Code <sup>2</sup> (#known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear			
YC.	AA**	US-2002/0040153-A1	04-04-2003	Petersen				
)	AB**	US-6,258,842-B1	07-10-2001	Petersen et al.				
	AC**	US-6,365,747-B1	02-02-2002	Dall'Asta et al.	·			
	AD**	US-2004/0132808-A1	07-08-2004	Petersen et al.				
	AE**	US-5,627,196-A	05-06-1997	Hibschman et al.				

<sup>\*\*</sup> Pursuant to the Notice issued by the United States Patent and Trademark Office dated July 11, 2003 waiving the requirements of 37 C.F.R. § 1.98(a)(2)(i), a copy/copies of the United States Patent on PTO/S808 is/are not being submitted.

	FOREIGN PATENT DOCUMENTS							
Examiner	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines,			
Initials*		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>3</sup> (# known) MM-DD-YY		Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T⁰		
1/2	1	WO-01/43525-A2	06-21-2001	Rock et al.		Г		
	2	WO-99/14207-A1	03-25-1999	Berg Stefan		Г		
	3	WO-0 814 084-A1	12-29-1997	Eli Lilly Co.		Г		
	4	WO-96/24353-A1	08-15-1996	Eli Lilly Co.				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
YC	5	AUQUIER, P., et al., Int. J. Psychiatr. Clin. Pract., 2003, Vol. 7, pp. 259-268.	
	6	BEIN, E., et al., Behav. Pharmacol., 2003, Vol. 14, p. S37.	
	7	FISH, E.W., et al., J. Pharmacol. Exp. Ther., October 30, 2003, Fast Forward publ. as DOI: 10.1124/jpet.103.058206, 2004.	
	8	SANCHEZ, Connie, et al., Psychopharmacology, 2003, Vol. 167, pp. 353-362.	
	9	SANCHEZ, Connie, et al., Behav. Pharmacol., 2003, Vol. 14, pp. 465-470.	
	10	SANCHEZ, Connie, et al., "Escitalopram versus citalopram: the surprising role of the Renantiomer", Phsychopharmacology (Berl.), 2004.	
	11	HYTTEL, J., et al., "The pharmacological effect of citalopram resides in the (S) - (+)-enantiomer", Journal of Neural Transmission, 1992, Vol. 88, No. 2, pp. 157-160.	
	12	SANCHEZ, Connie, et al., "Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression", Psychopharmacology, 1997, Vol. 129, pp. 197-205.	
	13	LEPOLA, U., et al., "Citalopram in the Treatment of Social Phobia: A Report of Three Cases", Pharmacopsychiatry, September 1994, Vol. 27, No. 5, pp. 186-188.	
	14	HUMBLE, M., et al., "Serotonin, Panic Disorder and Agoraphobia: Short-Term and Long-Term Efficacy of Citalopram in Panic Disorders", International Clinical Psychopharmacology, 1992, Vol. 6, No. Suppl. 5, pp. 21-39.	

Examiner Signature	Von	Chan		Date Considered	2/2/06	
	<i>-71 T</i>	/	·			

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known		
INFORMATION DISCLOSURE				Application Number	10/644,576	
				Filing Date	August 20, 2003	
STATEMENT BY APPLICANT			PLICANT	First Named Inventor	Connie Sanchez	
				Art Unit	N/A	
(Use as many sheets as necessary)			essary)	Examiner Name	Not Yet Assigned	
Sheet	2	of	2	Attorney Docket Number	05432/100M919-US5	

15 BOUWER, C., et al., "Use of the selective serotonin reuptake inhibitor citalogram in the				
Vc		treatment of generalized socail phobia", Journal of Affective Disorders, April 1998, Vol. 49, No.		
Ι'	ł	1, pp. 79-82.		

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date Considered Examiner 2/2/06 Signature

<sup>&#</sup>x27;Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached.